Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5 R59X knock‐in mice
European Journal of Neuroscience · 2024-06 · 59 (12) · 3337-3352
DOI: 10.1111/ejn.16350 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neuroscience, online erschienen am 23.04.2024. Verfasst von Xiaofan Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cannabidiol, Seizures, Behavior, Animal, Epileptic Syndromes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Cyclin‐dependent kinase‐like 5 (CDKL5) deficiency disorder (CDD) is caused by a loss‐of‐function mutation in CDKL5 gene, encoding a serine–threonine kinase highly expressed in the brain. CDD manifests with early‐onset epilepsy, autism, motor impairment and severe intellectual disability. While there are no known treatments for CDD, the use of cannabidiol has recently been introduced into clinical practice for neurodevelopmental disorders. Given the increased clinical utilization of cannabidiol, we examined its efficacy in the CDKL5 R59X knock‐in (R59X) mice, a CDD model based on a human mutation that exhibits both lifelong seizure susceptibility and behavioural deficits. We found that cannabidiol pre‐treatment rescued the increased seizure susceptibility in response to the chemoconvulsant pentylenetetrazol (PTZ), attenuated working memory and long‐term memory impairments, and rescued social deficits in adult R59X mice. To elucidate a potential mechanism, we compared the developmental hippocampal and cortical expression of common endocannabinoid (eCB) targets in R59X mice and their wild‐type littermates, including cannabinoid type 1 receptor (CB1R), transient receptor potential vanilloid type 1 (TRPV1) and 2 (TRPV2), G‐coupled protein receptor 55 (GPR55) and adenosine receptor 1 (A1R). Many of these eCB targets were developmentally regulated in both R59X and wild‐type mice. In addition, adult R59X mice demonstrated significantly decreased expression of CB1R and TRPV1 in the hippocampus, and TRPV2 in the cortex, while TRPV1 was increased in the cortex. These findings support the potential for dysregulation of eCB signalling as a plausible mechanism and therapeutic target in CDD, given the efficacy of cannabidiol to attenuate hyperexcitability and behavioural deficits in this disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Neurobehavior Testing Core, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Delia M Talos
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health, National Institute of Neurological Disorders and Stroke
- Hope4Harper Foundation
- Loulou Foundation
- Orphan Disease Center at the University of Pennsylvania
Zitieren
APA
Li, X., Yennawar, M., Wiest, A., O'Brien, W. T., Babrowicz, B., White, R. S., Talos, D. M., & Jensen, F. E. (2024). Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5 R59X knock‐in mice. European Journal of Neuroscience, 59(12), 3337-3352. https://doi.org/10.1111/ejn.16350
Vancouver
Li X, Yennawar M, Wiest A, O'Brien WT, Babrowicz B, White RS, et al. Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5 R59X knock‐in mice. European Journal of Neuroscience. 2024;59(12):3337-3352. doi:10.1111/ejn.16350
BibTeX
@article{Li2024,
author = {Li, Xiaofan and Yennawar, Madhumita and Wiest, Alyssa and O'Brien, William T and Babrowicz, Bergan and White, Rachel S and Talos, Delia M and Jensen, Frances E},
title = {Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5 R59X knock‐in mice},
journal = {European Journal of Neuroscience},
year = {2024},
volume = {59},
number = {12},
pages = {3337--3352},
doi = {10.1111/ejn.16350}
}
EUVIMED